To the Editor We read with great interest the article entitled “Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.”1 The authors concluded that tenofovir treatment was associated with a significantly lower risk of hepatocellular carcinoma (HCC) than entecavir treatment in treatment-naive patients with chronic hepatitis B. This study may potentially affect clinical practice, although Flemming and Terrault2 have stated in their accompanying editorial that this study should not lead to a widespread paradigm shift in selecting tenofovir treatment over entecavir treatment.
Kong Y, Jia J, Yang H. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. JAMA Oncol. 2019;5(6):915–916. doi:10.1001/jamaoncol.2019.0647
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: